Parabilis Medicines Analyst Price Targets - Benzinga

SPY770.40+0.10%QQQ724.76−0.57%BTC/USD82,256.26+0.84%DIA520.82+1.01%GLD381.14+1.37%TLT80.09+1.52%

Parabilis Medicines Inc

PBLSNASDAQ

Trade with Public

Trade with Public

$25.04

-0.85-3.28%

Last update: Oct 15, 2:56 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Parabilis Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for Parabilis Medicines (PBLS).

Price Target Range — 1 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$42Upside to Avg. PT+66.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 6, 2026	Leerink Partners	Andrew Berens	Initiate	Outperform	$40
Jul 6, 2026	Guggenheim	Michael Schmidt	Initiate	Buy	$40
Jul 6, 2026	B of A Securities	Tazeen Ahmad	Initiate	Buy	$45

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Parabilis Medicines with Outperform Rating, Announces Price Target of $40

Leerink Partners analyst Andrew Berens initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Outperform rating and announces Price Target of $40.

Benzinga Newsdesk

This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed outlook on top stocks. See full analyst rating changes & buy/sell recommendations for PBLS stock on Benzinga.

Avi Kapoor

PRO
B of A Securities Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $45

B of A Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $45.

Benzinga Newsdesk